Abogen Biosciences' Class 1 New Drug ABO2102, an mRNA Cancer Vaccine Targeting Multiple KRAS Mutations, Granted IND Approval in China for Solid Tumors
Abogen
Nucleic Acid Drug Developer
Source: PharmaBlock
The official website of the Center for Drug Evaluation (CDE) under the China National Medical Products Administration recently announced that Abogen's application for the new drug ABO2102 has received clinical trial authorization by default.ABO2102 Monotherapy or in Combination with SintilimabKRASLocally Advanced or Metastatic Solid Tumors with Mutations. Public information shows that ABO2102, developed by Abogen, isCovering multiple types simultaneouslyKRASNovel mRNA tumor vaccine with mutations, suitable for carriersKRASPatients with solid tumors harboring any of the five common mutations. The product has received clinical trial approval from the U.S. FDA this May.
KRASMutation is one of the most common oncogenic mutations in solid tumors, often associated with malignant tumors:KRASThe mutation occurs in approximately 85% of pancreatic cancer cases, about 40% of colorectal cancer cases, and around 30% of non-small cell lung cancer cases. KRAS has long been considered an "undruggable" target due to its relatively smooth protein surface and the lack of drug-binding "pockets," among other unique properties. Although breakthroughs have been made in recent years with small-molecule inhibitors targeting KRAS G12C, some limitations still need to be addressed, such as...Inevitable drug resistance, survival benefits for some patients still need improvement, etc.。KRASThere is an unmet clinical need in the clinical treatment of mutant tumors.
According toAbogen Biosciences Press Release Introduction,ABO2102 Therapeutic Cancer Vaccine Demonstrates Strong Anti-Tumor Activity in Preclinical Studies and Achieves Broad Coverage of HLA (Human Leukocyte Antigen) Subtypes. The vaccine features a multi-target antigen design:Simultaneously encoding 5 commonKRASThe mRNA molecules of mutant antigens are translated into antigens within the cell, and then presented via MHC-I/II molecules, activating a dual immune response of CD8⁺ cytotoxic T cells and CD4⁺ helper T cells, achieving...KRASPrecise Recognition and Attack of Mutant Antigens.Therefore, this vaccine product can cover a wider range ofKRASType of mutation.
In addition, ABO2102 can induce the sustained expansion of specific T cells, establish long-term immune memory, and achieve a breakthrough.Traditional KRAS G12C InhibitorDue to the single target and the difficulty in coping with the adaptive evolution of the tumor microenvironment,Dilemma of Drug Resistance. Preclinical data show that the T cells activated by this vaccine can accurately identifyKRASNew antigens on the surface of mutated cells effectively kill tumor cells.This endogenous immune response not only avoids the common off-target toxicity of targeted drugs but also continuously suppresses tumor recurrence through immune memory mechanisms.Preclinical studies also showed that ABO2102 combined with PD-1 inhibitor has a synergistic effect, further enhancing anti-tumor efficacy.
Abogen's press release concluded,ABO2102 Aims to Shift the Paradigm of KRAS-Targeted Therapy from "Passive Inhibition" to "Active Immune Clearance". This vaccine, based on a multi-epitope antigen design, precisely targets high-incidence cancers such as pancreatic cancer, non-small cell lung cancer, and colorectal cancer. With its off-the-shelf advantage, ABO2102 can be used for salvage therapy in advanced patients as well as adjuvant treatment post-surgery in early stages. Additionally, the vaccine can be combined with chemotherapy, radiotherapy, or immune checkpoint inhibitors to establish a multidimensional synergistic cancer treatment system.
Disclaimer:
The content of the article is for reference only and does not constitute investment advice. Investors who take action based on this information bear their own risks. The article maintains a neutral stance on the statements and viewpoints presented, and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content. Readers are advised to use it solely as a reference and assume full responsibility for their actions.
ICNS 2025
Booths are booking up fast!
Scan to consult immediately
Phone: 13816031174
(Same as WeChat)
Sponsorship forms include but are not limited toSpeaking slots, exhibition booths, color pages in conference brochures, dinner sponsorship, promotional materials for the conference, etc.